These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34376311)

  • 1. A targeted approach to phosphoinositide-3-kinase/Akt/mammalian target of rapamycin-induced hyperglycemia.
    Cheung YM; McDonnell M; Hamnvik OR
    Curr Probl Cancer; 2022 Feb; 46(1):100776. PubMed ID: 34376311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management.
    Khan KH; Wong M; Rihawi K; Bodla S; Morganstein D; Banerji U; Molife LR
    Oncologist; 2016 Jul; 21(7):855-60. PubMed ID: 27151652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
    Gallagher EJ; Fierz Y; Vijayakumar A; Haddad N; Yakar S; LeRoith D
    Oncogene; 2012 Jul; 31(27):3213-22. PubMed ID: 22037215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers.
    Shan KS; Bonano-Rios A; Theik NWY; Hussein A; Blaya M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
    Ediriweera MK; Tennekoon KH; Samarakoon SR
    Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer].
    ; ; ;
    Zhonghua Zhong Liu Za Zhi; 2022 Jul; 44(7):673-692. PubMed ID: 35880333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of the PI3K/AKT/mTOR pathway in human malignancies; trend of current clinical trials.
    Davoodi-Moghaddam Z; Jafari-Raddani F; Delshad M; Pourbagheri-Sigaroodi A; Bashash D
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):15293-15310. PubMed ID: 37594532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
    Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
    Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
    Alzahrani AS
    Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the PI3K-AKT-mTOR signaling network in cancer.
    Khan KH; Yap TA; Yan L; Cunningham D
    Chin J Cancer; 2013 May; 32(5):253-65. PubMed ID: 23642907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
    Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
    Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
    Zou CY; Smith KD; Zhu QS; Liu J; McCutcheon IE; Slopis JM; Meric-Bernstam F; Peng Z; Bornmann WG; Mills GB; Lazar AJ; Pollock RE; Lev D
    Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment.
    Liu D; Weintraub MA; Garcia C; Goncalves MD; Sisk AE; Casas A; Harding JJ; Harnicar S; Drilon A; Jhaveri K; Flory JH
    Cancer Med; 2022 Apr; 11(8):1796-1804. PubMed ID: 35212193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of mTOR Signaling as a Therapeutic Target in Cancer.
    Popova NV; Jücker M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors.
    Zhang Y; Yan H; Xu Z; Yang B; Luo P; He Q
    Expert Opin Drug Metab Toxicol; 2019 Sep; 15(9):767-774. PubMed ID: 31478386
    [No Abstract]   [Full Text] [Related]  

  • 18. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.
    Wu P; Hu YZ
    Curr Med Chem; 2010; 17(35):4326-41. PubMed ID: 20939811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer.
    Yu L; Wei J; Liu P
    Semin Cancer Biol; 2022 Oct; 85():69-94. PubMed ID: 34175443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK).
    Huang X; You L; Nepovimova E; Psotka M; Malinak D; Valko M; Sivak L; Korabecny J; Heger Z; Adam V; Wu Q; Kuca K
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2237209. PubMed ID: 37489050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.